Eli Lilly and Company (LLY)
What changed in recent filings
- Revenue +48% YoYQuarter ended Jun 30, 2026
- United States segment 69% → 63%Jun 30, 2024 → Jun 30, 2026
- Institutions — 3 new · 4 added · 4 reduced13F · as of end of 2026 Q2
What changed in recent SEC filings — factual, not a buy/sell recommendation.
Eli Lilly and Company recent earnings releases
Based on SEC filings. The release date is the day the earnings filing (8-K) was accepted; for quarters where that filing was not found, the periodic report filing date is shown.
- 26Q2Released Aug 5, 2026Revenue +47.7% YoY · EPS $7.94Released before the open: Aug 4 close → Aug 5 close, the stock moved +4.9% · over the same window, market -0.2% · sector +0.5%
- 26Q1Released Apr 30, 2026Revenue +55.5% YoY · EPS $8.26Released before the open: Apr 29 close → Apr 30 close, the stock moved +9.8% · over the same window, market +1.0% · sector +1.0%
- 25Q4Released Feb 4, 2026Revenue +42.6% YoY · EPS $7.39Released before the open: Feb 3 close → Feb 4 close, the stock moved +10.3% · over the same window, market -0.5% · sector +0.1%
- 25Q3Released Oct 30, 2025Revenue +53.9% YoY · EPS $6.21Released before the open: Oct 29 close → Oct 30 close, the stock moved +3.8% · over the same window, market -1.1% · sector +0.0%
The next earnings release is estimated around Oct 29, 2026 (calculated from how long this company has taken between quarter end and filing; it is not a date announced by the company).
Institutions holding Eli Lilly and Company
How many of the institutions we track reported holding this stock, quarter by quarter.
2019 Q1: 5 → 2026 Q2: 16 institutions
Counts the 52 institutions we track that reported holding this stock — their full reported holdings, not just the largest positions. Not the total number of institutional holders in the US. Figures are as of quarter-end and disclosed up to 45 days later. Descriptive only — not investment advice.
Which institutions hold Eli Lilly and Company
Institutions we track that reported holding this stock in their most recent 13F.
- National Pension Service (Korea)1.30% of portfolio · held as of 2019 Q1 or earlier
- Dodge & Cox0.03% of portfolio · held as of 2019 Q1 or earlier
- PRIMECAP Management6.51% of portfolio · held as of 2019 Q1 or earlier
- Caisse de depot (Quebec)1.38% of portfolio · held as of 2019 Q1 or earlier
- Capital World Investors2.25% of portfolio · held as of 2020 Q3 or earlier
- Temasek Holdings (Singapore)0.49% of portfolio · since 2024 Q2
- Point72 Asset Management0.01% of portfolio · since 2025 Q1
- Harris Associates (Oakmark)under 0.01% of portfolio · since 2025 Q2
- Bridgewater Associates0.43% of portfolio · since 2025 Q3
- Tudor Investment Corp0.05% of portfolio · since 2025 Q4
- Soros Fund Management0.33% of portfolio · since 2025 Q4
- Sands Capital Management0.20% of portfolio · since 2026 Q1
- ARK Invest0.60% of portfolio · since 2026 Q1
- Duquesne Family OfficeNew this quarter0.28% of portfolio · since 2026 Q2
- BlackstoneNew this quarterunder 0.01% of portfolio · since 2026 Q2
- Glenview Capital ManagementNew this quarter1.26% of portfolio · since 2026 Q2
Based on 13F filings — quarter-end holdings, disclosed up to 45 days later. Holding a stock is a fact we report, not a recommendation to buy or sell.
Q2 2026 13F recap — stocks several institutions bought and sold together →Company overview
A pharma company selling GLP-1 obesity/diabetes drugs (Mounjaro, Zepbound). It also develops Alzheimer's and other neuroscience drugs.
What is the Biotech & Health sector?
Pharma, biotech, and medical devices. Driven by trial-result events.
Eli Lilly and Company is classified under the Biotech & Health sector. See peers below.
Eli Lilly and Company key financials
Based on SEC filings · as of Jun 30, 2026
Tap a metric name to see its meaning in the glossary.
Eli Lilly and Company vs Biotech & Health sector benchmark
Median of 38 representative sector stocks · SEC filings · factual comparison (not advice)
A simple comparison to the sector benchmark. Higher or lower doesn’t mean good/bad or buy/sell.
LLY revenue by segment summary
SEC 10-Q · segment totals cross-checked against total revenue
2026-06-30 revenue was $23.0B, +47.7% YoY.
The largest segment is US, 62.7% of revenue — a highly concentrated structure.
Recent revenue growth was led mainly by the US segment (about 49% of the increase).
Full segment weights, YoY changes, and an AI synthesis are available in the detailed analysis.
LLY segment revenue mix trend
Quarterly change in segment revenue share · verified from SEC filings
2 quarters with a different segment breakdown were omitted (filing basis changed).
ETFs holding Eli Lilly and Company
Per SEC N-PORT · 2026-06-30 · by weight · factual
LLY on Stocklore
- Revenue by segment — segment weights verified from SEC filings, YoY changes, growth drivers and concentration
- Financials & earnings quality — 6 metrics (FCF conversion, ROIC, net debt, etc.) to gauge profit quality
- 13F institutional holdings — holdings and weight changes of major institutions (45-day delay)
- Sector-relative metrics — Valuation and growth compared with the Biotech & Health average
Peers · Biotech & Health
LLY FAQ
What is Eli Lilly and Company (LLY)?
A pharma company selling GLP-1 obesity/diabetes drugs (Mounjaro, Zepbound). It also develops Alzheimer's and other neuroscience drugs.
What sector is Eli Lilly and Company in?
Eli Lilly and Company is classified under Biotech & Health. Pharma, biotech, and medical devices. Driven by trial-result events.
What are Eli Lilly and Company's key financials?
As of Jun 30, 2026 in SEC filings: Revenue growth (YoY) 49.6%, Net margin 33.5%, ROE 77.8%, Debt-to-equity 1.41x. Definitions and interpretation are available on Stocklore.
What are Eli Lilly and Company's main revenue segments?
The largest segment is US, about 62.7% of revenue. Segment totals are cross-checked against total revenue from SEC filings.
Where can I analyze Eli Lilly and Company (LLY) stock?
On Stocklore you can see LLY's financials & earnings quality, 13F institutional holdings, and sector-relative metrics in one place. This page is for information and tools — not a buy/sell recommendation.
Data sources: SEC EDGAR (financials & filings), 13F (institutional holdings, as of quarter-end), market data. This page is for information and analysis tools — it does not recommend buying or selling any security. Investment decisions and responsibility are your own.